StageZero Life Sciences (TSX:SZLS) Price-to-Tangible-Book : (As of Apr. 30, 2024)

View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences Price-to-Tangible-Book?

As of today (2024-04-30), StageZero Life Sciences's share price is C$0.04. StageZero Life Sciences's Tangible Book per Share of Sep. 2023 for the quarter that ended in Sep. 2023 was C$-0.10. Hence, StageZero Life Sciences's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for StageZero Life Sciences's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, StageZero Life Sciences's highest Price to Tangible Book Ratio was 146.84. The lowest was 12.00. And the median was 19.88.

TSX:SZLS's Price-to-Tangible-Book is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 2.52
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, StageZero Life Sciences's share price is C$0.04. StageZero Life Sciences's Book Value per Sharefor the quarter that ended in Sep. 2023 was C$-0.10. Hence, StageZero Life Sciences's P/B Ratio of today is .

StageZero Life Sciences Price-to-Tangible-Book Historical Data

The historical data trend for StageZero Life Sciences's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences Price-to-Tangible-Book Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Tangible-Book

Get a 7-Day Free Trial

StageZero Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of StageZero Life Sciences's Price-to-Tangible-Book

For the Diagnostics & Research subindustry, StageZero Life Sciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StageZero Life Sciences's Price-to-Tangible-Book Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's Price-to-Tangible-Book falls into.

StageZero Life Sciences Price-to-Tangible-Book Calculation

StageZero Life Sciences's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2023 )
	=	0.04	/	-0.1
	=

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

StageZero Life Sciences Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences (TSX:SZLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

SZLSF:USA 61N1:Germany

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines